Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu F, Huang S, Liu X, Chen Q, Zhuang C, Zhao H, Han J, Jaen AM, Do TH, Peter JG, Dorado AG, Tirador LS, Zabat GMA, Villalobos REM, Gueco GP, Botha LLG, Iglesias Pertuz SP, Tan J, Zhu K, Quan J, Lin H, Huang Y, Jia J, Chu X, Chen J, Chen Y, Zhang T, Su Y, Li C, Ye X, Wu T, Zhang J, Xia N; COVID-19-PRO-003 Study Team.
Zhu F, et al. Among authors: botha llg.
Lancet Respir Med. 2023 Dec;11(12):1075-1088. doi: 10.1016/S2213-2600(23)00349-1. Epub 2023 Nov 15.
Lancet Respir Med. 2023.
PMID: 37979588
Free PMC article.
Clinical Trial.